- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
Reiss RF. Blood donor well-being: a primary responsibility of blood collection agencies.
Annals of Clinical & Laboratory Science. 2011;41(1):3–7. [
PubMed: 21325247]
- 9.
- 10.
Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply and emphasis on the management of donation-induced iron depletion.
Transfusion Medicine. 2008;18:13–27. [
PubMed: 18279189]
- 11.
Eder A, et al. Selection criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence), and future (hemovigilance).
Transfusion Medicine Reviews. 2009;23(3):205–220. [
PubMed: 19539875]
- 12.
Moreno J. “Creeping precautionism” and the blood supply.
Transfusion. 2003;43:840–842. [
PubMed: 12823739]
- 13.
Farrugia A. The mantra of blood safety: time for a new tune?
Vox Sanguinis. 2004;86:1–7. [
PubMed: 14984553]
- 14.
- 15.
- 16.
- 17.
- 18.
Heddle NM. Evidence-based decision making in transfusion medicine.
Vox Sanguinis. 2006;91(3):214–220. [
PubMed: 16958833]
- 19.
Vamvakas EC. Evidence-based practice of transfusion medicine: is it possible and what do the words mean?
Transfusion Medicine Reviews. 2004;18(4):267–278. [
PubMed: 15497127]
- 20.
Franklin IM. Is there a right to donate blood? Patient rights; donor responsibilities.
Transfusion Medicine. 2007;17(3):161–168. [
PubMed: 17561856]
- 21.
Brooks JP. The rights of blood recipients should supersede any asserted rights of blood donors.
Vox Sanguinis. 2004;87(4):280–286. [
PubMed: 15585024]
- 22.
Dodd RY. Current estimates of transfusion safety worldwide.
Developments in Biological Standardization (Basel). 2005;120:3–10. [
PubMed: 16050149]
- 23.
Seifried E, et al. How much blood is needed?
Vox Sanguinis. 2011;100:10–21. [
PubMed: 21175652]
- 24.
Custer B, et al. Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply.
Medical Decision Making. 2005;25(5):571–582. [
PubMed: 16160212]
- 25.
- 26.
Crookston KP, Wilkinson SL, Simon TL. Recruitment and screening of donors and the collection, processing and testing of blood. In: Simon TL, et al., editors. Rossi's Principles of transfusion medicine. 4th edition. Oxford: Wiley-Blackwell; 2009.
- 27.
Busch MP. Retroviruses and blood transfusion: the lessons learnt and challenges ahead. In: Nance SJ, editor. Blood safety: current challenges. Bethesda, MD: AABB; 1992. pp. 1–44.
- 28.
Stigum H, et al. Risk behavior in Norwegian blood donors.
Transfusion. 2001;4(12):1480–1485. [
PubMed: 11778060]
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
de Vries RRP, Faber JC, Strengers PFW. Haemovigilance: an effective tool for improving transfusion practice.
Vox Sanguinis. 2011;100(1):60–67. [
PubMed: 21175656]
- 35.
Van der Bij AK, et al. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands.
Transfusion. 2006;46(10):1729–1736. [
PubMed: 17002629]
- 36.
Munsterman KA, et al.
American Red Cross ARCNET Study Group. Assessment of motivations for return donation among deferred blood donors.
Transfusion. 1998;38(1):45–50. [
PubMed: 9482393]
- 37.
Custer B, et al. The consequences of temporary deferral on future whole blood donation.
Transfusion. 2007;47(8):1514–1523. [
PubMed: 17655597]
- 38.
Kissinger P, et al. Applications of computer assisted interviews to sexual behaviour research.
American Journal of Epidemiology. 1999;149:950–954. [
PubMed: 10342804]
- 39.
Sanchez AM, et al. Blood donor perceptions of health history screening.
Transfusion. 2003;43:165–172. [
PubMed: 12559011]
- 40.
Chassaigne M. Recent trends in donor selection and donor recruitment in Europe: French experience. Vox Sanguinis. 1996;70(Suppl.):147–153.
- 41.
Goldman M, et al. The Canadian donor health assessment questionnaire: can it be improved?
Transfusion. 2006;46:2169–2175. [
PubMed: 17176331]
- 42.
Williams AE, et al. Estimates of infectious disease risk factors in US blood donors.
Journal of the American Medical Association. 1997;277:967–972. [
PubMed: 9091668]
- 43.
Alaishuski LA, Grim RD, Domen RE. The informed consent process in whole blood donation.
Archives of Pathology & Laboratory Medicine. 2008;132(6):947–951. [
PubMed: 18517277]
- 44.
- 45.
Falter E, Reiss RF. Effect of counselling rejected blood donors to seek health care.
Patient Counselling and Health Education. 1981;3(2):67–70. [
PubMed: 10252498]
- 46.
Lee CK, et al. Prevention of transfusion-transmitted hepatitis E by donor-initiated self-exclusion.
Transfusion Medicine. 2005;15(2):133–135. [
PubMed: 15859980]
- 47.
Zou S, et al. Current impact of the confidential unit exclusion option.
Transfusion. 2004;44(5):651–657. [
PubMed: 15104644]
- 48.
Kean CA, et al. A study of CUE.
Transfusion. 1990;30:707–709. [
PubMed: 2219257]
- 49.
O'Brien SF, et al. Evaluation of the confidential unit exclusion form: the Canadian Blood Services experience.
Vox Sanguinis. 2010;98:138–144. [
PubMed: 19754523]
- 50.
Trouern-Trend J, et al. A case-controlled multi-centre study of vasovagal reactions in blood donors: influence of sex, age, weight, blood pressure and pulse.
Transfusion. 1999;39:316–320. [
PubMed: 10204597]
- 51.
Sorensen B, Johnsen S, Jorgensen J. Complications related to blood donation: a population-based study.
Vox Sanguinis. 2008;94:132–137. [
PubMed: 18028259]
- 52.
Newman BH, et al. Donor reactions in high-school donors: the effects of sex, weight, and collection volume.
Transfusion. 2006;46:284–288. [
PubMed: 16441608]
- 53.
Eder AF, et al. Adverse reactions to allogeneic whole blood donation by 16- and 17-year-olds.
Journal of the American Medical Association. 2008;299(19):2279–2286. [
PubMed: 18492969]
- 54.
- 55.
- 56.
Eder A, et al. The American Red Cross donor vigilance programme: complications of blood donations reported in 2006.
Transfusion. 2008;48:1809–1819. [
PubMed: 18631167]
- 57.
Janetko K, et al. Effects of blood donation on the physical fitness and hemorheology of healthy elderly donors.
Vox Sanguinis. 1998;75:7–11. [
PubMed: 9745147]
- 58.
McVay P, et al. Donation reactions among autologous donors.
Transfusion. 1990;30(3):249–252. [
PubMed: 2315998]
- 59.
Pindyck J, Avoron J, Kuryan M. Blood donation by the elderly. Clinical and policy considerations.
Journal of the American Medical Association. 1987;257:1186–1188. [
PubMed: 3806916]
- 60.
Simon T, et al. Characteristics of elderly blood donors.
Transfusion. 1991;31:693–697. [
PubMed: 1926311]
- 61.
Goldman M, et al. Effect of changing the age criteria for blood donors.
Vox Sanguinis. 2007;92(4):368–372. [
PubMed: 17456161]
- 62.
Zeiler T, et al. The safety of blood donation by elderly blood donors.
Vox Sanguinis. 2011;101(4):313–319. [
PubMed: 21535439]
- 63.
Müller-Steinhardt M, et al. Safety and frequency of whole blood donations from elderly donors.
Vox Sanguinis. 2012;102(2):134–139. [
PubMed: 21806633]
- 64.
- 65.
Kitchen A, Barbara J. Transfusion-transmitted infections. In: Murphy M, Pamphilon D, editors. Practical transfusion medicine: 221–224. Blackwell Publishing Ltd; Oxford, UK: 2005.
- 66.
Wiltbank TB, et al. Faint and prefaint reactions in whole-blood donors: an analysis of predonation measurements and their predictive value.
Transfusion. 2008;48(9):1799–1808. [
PubMed: 18482188]
- 67.
Klein H, Anstee D. Mollison's blood transfusion in clinical medicine. 11th edition. London, UK: Blackwell Publishing Ltd; 2005.
- 68.
Boulton F. The 13% rule. Comments. Transfusion Today. 2007;71:7–9.
- 69.
Lemmens HJM, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients.
Obesity Surgery. 2006;16:773–776. [
PubMed: 16756741]
- 70.
Guide to the preparation, use and quality assurance of blood components. 16th edition. Strasbourg: Council of Europe; 2010.
- 71.
Mackowiak PA. Temperature regulation and the pathogenesis of fever. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th edition. Philadelphia, PA: Elsevier Churchill Livingstone; 2005.
- 72.
- 73.
Stainsby D, et al. Safety of blood donation from individuals with treated hypertension or non-insulin dependent type 2 diabetes – a systematic review.
Vox Sanguinis. 2010;98(3):431–440. [
PubMed: 19878496]
- 74.
Beutler E, West C. Haematolologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia and hemoglobin levels and mean corpuscular volume.
Blood. 2005;106:740–745. [
PMC free article: PMC1895180] [
PubMed: 15790781]
- 75.
Mast AE, et al. NHLBI Retrovirus Epidemiology Donor Study-II. Demographic correlates of low haemoglobin deferral among prospective whole blood donors.
Transfusion. 2010;50(8):1794–1802. [
PMC free article: PMC3003699] [
PubMed: 20412525]
- 76.
- 77.
- 78.
Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion.
Transfusion Medicine. 2008;18(1):13–27. [
PubMed: 18279189]
- 79.
Eder A. Evidence-based selection criteria to protect blood donors.
Journal of Clinical Apheresis. 2010;25:331–337. [
PubMed: 20824625]
- 80.
Bianco C, et al. Maintaining iron balance in women blood donors of childbearing age; summary of a workshop.
Transfusion. 2002;42:798–805. [
PubMed: 12147035]
- 81.
Cable RG, et al. for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study.
Transfusion. 2012;52(4):702–711. [
PMC free article: PMC3618489] [
PubMed: 22023513]
- 82.
Røsvik AS, et al. The effect of blood donation frequency on iron status.
Transfusion and Apheresis Science. 2009;41:165–169. [
PubMed: 19819187]
- 83.
Cable RG, et al. for the NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study.
Transfusion. 2011;51(3):511–522. [
PMC free article: PMC3050998] [
PubMed: 20804527]
- 84.
Mittal R, et al. Evaluation of iron stores in blood donors by serum ferritin.
Indian Journal of Medical Research. 2006;124(6):641–646. [
PubMed: 17287551]
- 85.
Alvarez-Ossorio L, et al. Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors.
Transfusion Medicine. 2000;10(2):107–112. [
PubMed: 10849379]
- 86.
Farrugia A. Iron and blood donation – an under-recognised safety issue.
Developmental Biology (Basel). 2007;127:137–146. [
PubMed: 17486886]
- 87.
O'Meara A, et al. The value of routine ferritin measurement in blood donors.
Transfusion. 2011;51(10):2183–2188. [
PubMed: 21517893]
- 88.
- 89.
Djalali M, et al. The effect of repeated blood donations on the iron status of Iranian blood donors attending the Iranian blood transfusion organization.
International Journal for Vitamin and Nutrition Research. 2006;76(3):132–137. [
PubMed: 17048192]
- 90.
Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed.
Transfusion. 2006;46(10):1667–1681. [
PubMed: 17002622]
- 91.
Boulton F, et al. A study of the iron and HFE status of blood donors, including a group who failed the initial screen for anaemia.
British Journal of Haematology. 2000;108:434–439. [
PubMed: 10691878]
- 92.
- 93.
- 94.
Gilcher RO, Smith JW. Apheresis: principles and technology of hemapheresis. In: Simon TL, et al., editors. Rossi's Principles of transfusion medicine. 4th edition. AABB Press & Wiley-Blackwell; 2009.
- 95.
Hanson SA, France CR. Predonation water ingestion attenuates negative reaction to blood donation.
Transfusion. 2004;44(6):924–928. [
PubMed: 15157261]
- 96.
Newman B, et al. The effect of a 473-mL (16-oz) water drink on vasovagal donor reaction rates in high-school students.
Transfusion. 2007;47:1524–1533. [
PubMed: 17655598]
- 97.
Wieling W, et al. Physiologic strategies to prevent fainting responses during or after whole blood donation.
Transfusion. 2011;51(12):2727–2738. [
PubMed: 21645008]
- 98.
Ditto B, et al. Reducing reactions to blood donation with applied muscle tension: a randomized controlled trial.
Transfusion. 2003;43:1269–1275. [
PubMed: 12919430]
- 99.
Ditto B, France CR. The effects of applied tension on symptoms in French-speaking blood donors: a randomized trial.
Health Psychology. 2006;25:433–437. [
PubMed: 16719616]
- 100.
Ditto B, et al. Dismantling applied tension: mechanisms of a treatment to reduce blood donation-related symptoms.
Transfusion. 2007;47:2217–2222. [
PubMed: 17714419]
- 101.
Ditto B, et al. Effects of applied muscle tension on the likelihood of blood donor return.
Transfusion. 2009;49:858–862. [
PubMed: 19175551]
- 102.
Eder AF, et al. Transfusion-related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross.
Transfusion. 2007;47(4):599–607. [
PubMed: 17381617]
- 103.
Chapman C, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma.
Transfusion. 2009;49(3):440–452. [
PubMed: 18980623]
- 104.
Reil A, et al. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors.
Vox Sanguinis. 2008;95(4):313–317. [
PubMed: 19138261]
- 105.
Sorensen B, Johnsen S, Jorgensen J. Complications related to blood donation: a population-based study.
Vox Sanguinis. 2008;94:132–137. [
PubMed: 18028259]
- 106.
US Army Medical Services.
Army Regulation 40–8. Temporary flying restrictions due to exogenous factors affecting aircrew efficiency. Department of the Army; Washington DC: 2007. [10 August 2012].
http://www.army.mil/usapa/epubs/pdf/r40_8.pdf.
- 107.
Baldo V, et al. Occupational risk of blood-borne viruses in healthcare workers: a 5-year surveillance program.
Infection Control and Hospital Epidemiology. 2002;23(6):325–327. [
PubMed: 12083236]
- 108.
Do AN, et al. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States.
Infection Control and Hospital Epidemiology. 2003;24(2):86–96. [
PubMed: 12602690]
- 109.
Elder A, Paterson C. Sharps injuries in UK health care: a review of injury rates, viral transmission and potential efficacy of safety devices.
Occupational Medicine. 2006;56(8):566–574. [
PubMed: 17065314]
- 110.
Sonder GJ, et al. Occupational exposure to bloodborne viruses in the Amsterdam police force, 2000––2003.
American Journal of Preventive Medicine. 2005;28(2):169–174. [
PubMed: 15710272]
- 111.
Peng B, et al. Sharps injury and body fluid exposure among health care workers in an Australian tertiary hospital.
Asia Pacific Journal of Public Health. 2008;20(2):139–147. [
PubMed: 19124307]
- 112.
Smith JW, Burgstaler EA. Blood component collection by apheresis. In: Roback JD, et al., editors. AABB Technical Manual. 16th edition. Bethesda, Md: AABB; 2008. pp. 229–239.
- 113.
Harris SB, Hillyer CD. Blood banking and transfusion medicine. Edinburgh: Churchill Livingstone (Elsevier); 2008. Blood manufacturing: component preparation, storage and transportation; pp. 183–202.
- 114.
- 115.
Stroncek DF, et al. Sickle Hb polymerization in RBC components from donors with sickle trait prevents effective WBC reduction by filtration.
Transfusion. 2002;42(11):1466–1472. [
PubMed: 12421220]
- 116.
Ould Amar AK. Red blood cells from donors with sickle cell trait: a safety issue for transfusion?
Transfusion Medicine. 2006;16(4):248–253. [
PubMed: 16879152]
- 117.
- 118.
- 119.
Sanchez AM. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis.
Journal of the American Medical Association. 2001;286(12):1475–1481. [
PubMed: 11572740]
- 120.
Barton J, et al. Severity of iron load in hemochromatosis: effect of volunteer blood donation before diagnosis.
Transfusion. 2001;41:123–129. [
PubMed: 11161257]
- 121.
Leitman S, et al. Hemochromatosis subjects as allogeneic blood donors: a prospective study.
Transfusion. 2003;43(11):1538–1544. [
PubMed: 14617312]
- 122.
Hillyer C, et al. Comparable safety of blood donation in high-risk autologous donors versus non-high risk donors and directed donors in a hospital setting.
American Journal of Clinical Pathology. 1994;102(3):275–277. [
PubMed: 8085549]
- 123.
Klapper E, et al. Confirmation of the safety of autologous blood donation by patients awaiting heart or lung transplantation. A controlled study using hemodynamic monitoring.
The Journal of Thoracic and Cardiovascular Surgery. 1995;110(6):1594–1599. [
PubMed: 8523868]
- 124.
Mann M, Sacks HJ, Goldfinger D. Safety of autologous blood donation prior to elective surgery for a variety of potentially high-risk patients.
Transfusion. 1983;21(3):229–232. [
PubMed: 6602407]
- 125.
Owings DV, et al. Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use.
Journal of the American Medical Association. 1989;262(14):1963–1968. [
PubMed: 2789297]
- 126.
Speiss BD, et al. Autologous blood donation: hemodynamics in a high-risk patient population.
Transfusion. 1992;32(1):17–22. [
PubMed: 1731430]
- 127.
Aubuchon JP, Popovsky MA. The safety of preoperative autologous blood donation in the nonhospital setting.
Transfusion. 1991;31(6):513–517. [
PubMed: 1853445]
- 128.
- 129.
Johansson SG, et al. Passive IgE-sensitization by blood transfusion.
Allergy. 2005;60(9):1192–1199. [
PubMed: 16076307]
- 130.
Johansson SG, et al. High prevalence of IgE antibodies among blood donors in Sweden and Norway.
Allergy. 2005;60(10):1312–1315. [
PubMed: 16134999]
- 131.
Stern A, et al. Is allergy screening of blood donors necessary? A comparison between questionnaire answers and the presence of circulating IgE antibodies.
Vox Sanguinis. 1995;69(2):114–119. [
PubMed: 8585191]
- 132.
Weisbach V, et al. A pilot study of continuous ambulatory monitoring of blood pressure in repeated preoperative autologous transfusion.
Transfusion. 2006;46:934–941. [
PubMed: 16734809]
- 133.
Thomas SHL, et al. The haemodynamic responses to venesection and the effects of cardiovascular disease.
Clinical and Laboratory Haematology. 1992;14:201–208. [
PubMed: 1451400]
- 134.
Krumholz A, et al. Adverse reactions in blood donors with a history of epilepsy or seizures.
Transfusion. 1995;35(6):470–474. [
PubMed: 7770896]
- 135.
Krumholz A, et al. Regulations prohibiting blood donation by individuals with seizures or epilepsy are not necessary.
Medical Law. 1997;16(2):339–347. [
PubMed: 9212625]
- 136.
van der Linden GJ, Siegenbeek van Heukelom LH, Meinardi H. Blood donation, a risk for epileptic patients?
Vox Sanguinis. 1986;51(2):148–151. [
PubMed: 3776138]
- 137.
Ludlam C, Turner M. Managing the risk of transmission of variant Creutzfeldt-Jakob disease by blood products.
British Journal of Haematology. 2005;132:13–24. [
PubMed: 16371015]
- 138.
- 139.
Dzik WH, Okayama A. Can blood transfusion transmit disease-producing genes?
Transfusion. 1999;39:795–800. [
PubMed: 10504112]
- 140.
Memon A, Doll R. A search for unknown blood-borne oncogenic viruses.
International Journal of Cancer. 1994;58:366–368. [
PubMed: 8050819]
- 141.
Edgren G, et al. Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study.
Lancet. 2007;369(9574):1724–1730. [
PubMed: 17512857]
- 142.
Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation.
The Lancet Oncology. 2010;11(8):790–796. [
PubMed: 20451456]
- 143.
Yang H, et al. Can blood transfusion transmit cancer? A literature review.
Transfusion Medicine Reviews. 2010;24(3):235–243. [
PubMed: 20656190]
- 144.
- 145.
- 146.
Becker C, et al. Blood donors on medication – an approach to minimize drug burden for recipients of blood products and to limit deferral of donors.
Transfusion Medicine and Hemotherapy. 2009;36:107–113. [
PMC free article: PMC2928823] [
PubMed: 20823991]
- 147.
Stichtenoth D, Deicher H, Frolich J. Blood donors on medication. Are deferral periods necessary?
European Journal of Clinical Pharmacology. 2001;57(6–7):433–440. [
PubMed: 11699606]
- 148.
Park HD, et al. Evaluation of the transfusion safety of blood products and determination of plasma concentrations of acitretin and etretinate in patients receiving transfusions.
Transfusion. 2008;48(11):2395–2400. [
PubMed: 18657077]
- 149.
- 150.
- 151.
Suitability determination for donors of human cells, tissues, and cellular and tissue-based products: CJD and vCJD; Draft issue summaries, issue 2, Transmissible Spongiform Encephalopathies Advisory Committee Meeting; 18–19 January, 2001; Rockville, MD: US Food and Drug Administration; 2001. [10 August 2012].
http://www.fda.gov/ohrms/dockets/ac/01/briefing/3681b1_02.doc.
- 152.
Bronowicki JP, et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy.
New England Journal of Medicine. 1997;337(4):237–240. [
PubMed: 9227929]
- 153.
Ciancio A, et al. Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus.
Annals of Internal Medicine. 2005;142(11):903–909. [
PubMed: 15941697]
- 154.
Kinane D, et al. Bacteraemia following periodontal procedures.
Journal of Clinical Periodontology. 2005;32:708–713. [
PubMed: 15966875]
- 155.
Rajasuo A, et al. Bacteremia following surgical dental extraction with an emphasis on anaerobic strains.
Journal of Dental Research. 2004;83(2):170–174. [
PubMed: 14742658]
- 156.
Olsen I. Update on bacteraemia related to dental procedures.
Transfusion and Apheresis Science. 2008;39(2):173–178. [
PubMed: 18753008]
- 157.
- 158.
- 159.
Busch M, et al. Oversight and monitoring of blood safety in the United States.
Vox Sanguinis. 1999;77(2):67–76. [
PubMed: 10516550]
- 160.
Busch M. Lessons and opportunities from epidemiologic and molecular investigations of infected blood donors.
Transfusion. 2006;46(10):1663–1666. [
PubMed: 17002621]
- 161.
Dodd R. Current risk for transfusion transmitted infections.
Current Opinion in Haematology. 2007;14(6):671–676. [
PubMed: 17898573]
- 162.
- 163.
Alter H. Emerging, re-emerging and submerging infectious threats to the blood supply.
Vox Sanguinis. 2004;87(Suppl. s2):56–61. [
PubMed: 15209880]
- 164.
Busch M, Kleinman SN. Current and emerging infectious risks of blood transfusion.
Journal of the American Medical Association. 2003;289(8):959–962. [
PubMed: 12597733]
- 165.
Polizzotto M, et al. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006.
Transfusion. 2008;48(1):55–63. [
PubMed: 17894794]
- 166.
Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century.
Vox Sanguinis. 2011;100:92–98. [
PubMed: 21175659]
- 167.
Weinbaum CM, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.
Morbidity and Mortality Weekly Report (MMWR), Recommendations and Reports. 2008;57(RR08):1–20. [
PubMed: 18802412]
- 168.
Pereira A, et al. Do patient-related blood donors represent a threat to the safety of the blood supply?
Haematologica. 2002;87(4):427–433. [
PubMed: 11940488]
- 169.
Goldman M, et al. Reassessment of deferrals for tattooing and piercing.
Transfusion. 2009;49(4):648–654. [
PubMed: 19171003]
- 170.
- 171.
Gerlich WH, et al. HBsAg non-reactive HBV infection in blood donors. Transmission and pathogenicity. Journal of Medical Virology. 2007;(Suppl. 1):S32–S36.
- 172.
Satake M, et al. Infectivity of blood components with low HBV-DNA levels identified in a lookback program.
Transfusion. 2007;47(7):1197–1205. [
PubMed: 17581154]
- 173.
Cavalheiro Nde P. Sexual transmission of hepatitis C.
Revista do Instituto de Medicina Tropical de São Paulo. 2007;49(5):271–277. [
PubMed: 18026632]
- 174.
Cavalheiro Nde P, et al. Hepatitis C virus: molecular and epidemiological evidence of male-to-female transmission.
Brazilian Journal of Infectious Diseases. 2010;14(5):427–432. [
PubMed: 21221468]
- 175.
Nguyen O, et al. Acute hepatitis C infection with evidence of heterosexual transmission.
Journal of Clinical Virology. 2010;49(1):65–68. [
PubMed: 20667768]
- 176.
Orlando R, Lirussi F. Hepatitis C virus infection: sexual or non-sexual transmission between spouses? A case report and review of the literature.
Infection. 2007;35(6):465–468. [
PubMed: 17906840]
- 177.
Lock G, et al. Hepatitis C – contamination of toothbrushes: myth or reality?
Journal of Viral Hepatitis. 2006;13(9):571–573. [
PubMed: 16907842]
- 178.
- 179.
Sherertz RJ, Russell BA, Reuman PD. Transmission of hepatitis A by transfusion of blood products.
Archives of Internal Medicine. 1984;144(8):1579–1580. [
PubMed: 6087755]
- 180.
Noble RC, et al. Posttransfusion Hepatitis A in a neonatal intensive care unit.
Journal of the American Medical Association. 1984;252(19):2711–2715. [
PubMed: 6492349]
- 181.
Hollinger FB. Posttransfusion hepatitis type A.
Journal of the American Medical Association. 1983;250(17):2313–2317. [
PubMed: 6313973]
- 182.
Azimi PH, et al. Transfusion-acquired hepatitis A in a premature infant with secondary nosocomial spread in an intensive care nursery.
American Journal of Diseases of Children. 1986;40(1):23–27. [
PubMed: 3942103]
- 183.
- 184.
Lee CK, et al. Prevention of transfusion-transmitted hepatitis E by donor-initiated self exclusion.
Transfusion Medicine. 2005;15(2):133–135. [
PubMed: 15859980]
- 185.
- 186.
- 187.
Baggaley RF, et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis.
AIDS. 2006;20:805–812. [
PubMed: 16549963]
- 188.
Lefrère JJ. Human T-lymphotropic virus type I (HTLV-I): risk of transmission with transfusion.
La Presse Médicale. 2000;29(20):1134–1138. [
PubMed: 10901796]
- 189.
Eshima N, et al. Analysis of the infection system of human T-cell leukaemia virus type I based on a mathematical epidemic model.
Statistics in Medicine. 2001;20(24):3891–3900. [
PubMed: 11782041]
- 190.
Juhl D, et al. Detection of herpes simplex virus DNA in plasma of patients with primary but not with recurrent infection: implications for transfusion medicine?
Transfusion Medicine. 2010;20(1):38–47. [
PubMed: 19708895]
- 191.
Drew WL, et al. Frequency and duration of plasma CMV viraemia in seroconverting blood donors and recipients.
Transfusion. 2003;43(3):309–313. [
PubMed: 12675714]
- 192.
Cannon MJ, et al. Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort.
Journal of Infectious Diseases. 2009;199(11):1592–1598. [
PubMed: 19385734]
- 193.
Dollard SC, et al. Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort.
Transfusion. 2005;45:500–503. [
PubMed: 15819669]
- 194.
Regamey N, et al. Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients.
New England Journal of Medicine. 1998;339:1358–1363. [
PubMed: 9801396]
- 195.
- 196.
Orton S, Stramer S, Dodd R. Self-reported symptoms associated with West Nile Virus infection in RNA positive blood donors.
Transfusion. 2006;46:272–277. [
PubMed: 16441606]
- 197.
Brown JA, et al. West Nile viremic blood donors and risk factors for subsequent West Nile fever.
Vector-Borne and Zoonotic Diseases. 2007;7(4):479–488. [
PubMed: 17979539]
- 198.
Stramer SL. Reacting to an emerging safety threat: West Nile virus in North America.
Developments in Biologicals (Basel). 2007;127:43–58. [
PubMed: 17486880]
- 199.
Vamvakas EC. The development of West Nile virus safety policies by Canadian blood services: guiding principles and a comparison between Canada and the United States.
Transfusion Medicine Reviews. 2006;20(2):97–109. [
PubMed: 16565024]
- 200.
- 201.
- 202.
- 203.
- 204.
- 205.
- 206.
- 207.
- 208.
- 209.
Kitchen AD, Chiodini PL. Malaria and blood transfusion.
Vox Sanguinis. 2006;90(2):77–84. [
PubMed: 16430664]
- 210.
Garraud O. Measures to prevent transfusion-associated protozoal infections in non-endemic countries.
Travel Medicine and Infectious Disease. 2007;5(2):110–112. [
PubMed: 17298917]
- 211.
Kitchen AD, et al. Documented cases of post-transfusion malaria occurring in England: a review in relation to current and proposed donor-selection guidelines.
Vox Sanguinis. 2005;89(2):77–80. [
PubMed: 16101687]
- 212.
Reesink HW. European strategies against the parasite transfusion risk.
Transfusion clinique et biologique. 2005;12(1):1–4. [
PubMed: 15814284]
- 213.
Dias J, Silveira A, Schofield C. The impact of Chagas disease control in Latin America. A review.
Memorias Instituto Oswaldo Cruz, Rio de Janeiro. 2002;97(5):603–612. [
PubMed: 12219120]
- 214.
Moncayo A. Progress towards the elimination of transmission of Chagas disease in Latin America.
World Health Statistics Quarterly. 1997;50(3–4):195–198. [
PubMed: 9477549]
- 215.
Moraes-Souza H. Chagas infection transmission control: situation of transfusional transmission in Brazil and other countries of Latin America.
Memorias Instituto Oswaldo Cruz. 1999;94(Suppl. 1):419–423. [
PubMed: 10677769]
- 216.
Ponce C. Current situation of Chagas disease in Central America.
Memorias Instituto Oswaldo Cruz, Rio de Janeiro. 2007;102(Suppl. 1):41–44. [
PubMed: 17713679]
- 217.
- 218.
Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries.
Memorias Instituto Oswaldo Cruz. 2003;98(5):577–591. [
PubMed: 12973523]
- 219.
Moraes-Souza H, Bordin J. Strategies for prevention of transfusion-associated Chagas' disease.
Transfusion Medicine Reviews. 1996;10(3):161–170. [
PubMed: 8809967]
- 220.
Castro E. Chagas' disease: lessons from routine donation testing.
Transfusion Medicine. 2009;(19):16–23. [
PubMed: 19302451]
- 221.
O'Brien SF, et al. Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing.
Transfusion. 2008;48(4):755–761. [
PubMed: 18194375]
- 222.
Cable RG, Leiby DA. Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases.
Current Opinion in Hematology. 2003;10(6):405–411. [
PubMed: 14564169]
- 223.
- 224.
- 225.
Gubernot DM, et al. Transfusion-transmitted babesiosis in the United States: summary of a workshop.
Transfusion. 2009;49(12):2759–2771. [
PubMed: 19821952]
- 226.
Tonnetti L, et al. Transfusion-transmitted Babesia microti identified through hemovigilance.
Transfusion. 2009;49(12):2557–2563. [
PubMed: 19624607]
- 227.
Cardo LJ. Leishmania: risk to the blood supply.
Transfusion. 2006;46(9):1641–1645. [
PubMed: 16965594]
- 228.
Dey A, Singh S. Transfusion transmitted leishmaniasis: a case report and review of literature.
Indian Journal of Medical Microbiology. 2006;24(3):165–70. [
PubMed: 16912434]
- 229.
Blajchman M. Bacterial contamination of cellular blood components: risks, sources and control.
Vox Sanguinis. 2004;87(Suppl. 1):98–103. [
PubMed: 15200616]
- 230.
Wagner SJ. Transfusion-transmitted bacterial infection: risks, sources and interventions.
Vox Sanguinis. 2004;86(3):157–163. [
PubMed: 15078249]
- 231.
McDonald CP, et al. Relative values of the interventions of diversion and improved donor-arm disinfection to reduce the bacterial risk from blood transfusion.
Vox Sanguinis. 2004;86(3):178–182. [
PubMed: 15078252]
- 232.
- 233.
Leclercq A, et al. Fatal Yersinia enterocolitica biotype 4 serovar O:3 sepsis after red blood cell transfusion.
Transfusion. 2005;45(5):814–818. [
PubMed: 15847674]
- 234.
ECDC Technical Report. Risk assessment on Q fever. Stockholm: European Centre for Disease Prevention and Control; 2010.
- 235.
Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies.
British Medical Journal. 2000;321(7252):17–19. [
PMC free article: PMC27418] [
PubMed: 10875826]
- 236.
- 237.
- 238.
Ludlam C, Turner M. Managing the risk of transmission of variant Creutzfeldt-Jakob disease by blood products.
British Journal of Haematology. 2005;132:13–24. [
PubMed: 16371015]
- 239.
Wilson K, Ricketts M. Transfusion transmission of vCJD: a crisis avoided?
Lancet. 2004;384:477–479. [
PubMed: 15302172]
- 240.
Peden A, Ritchie D, Ironside J. Risks of transmission of variant Creutzfeldt-Jakob disease by blood transfusion.
Folia Neuropathologica. 2005;43(4):271–278. [
PubMed: 16416391]
- 241.
- 242.
- 243.
- 244.
- 245.
- 246.
Musto J, et al. Estimating the risk of blood donation associated with HIV risk behaviours.
Transfusion Medicine. 2008;18(1):49–54. [
PubMed: 18279192]
- 247.
- 248.
Alonso M, et al. Preventing transfusion-transmitted HIV infection in Latin America and the Caribbean: issues associated with blood donor interviews and sex between men.
Journal of Acquired Immune Deficiency Syndromes. 2009;51(Suppl. 1):S67–72. [
PubMed: 19384105]
- 249.
Donor selection criteria review (April 2011). London: Advisory Committee on the Safety of Blood, Tissues and Organs; 2011.
- 250.
- 251.
Beyrer c, et al. The global HIV epidemics among men who have sex with men. Washington DC: The International Bank for Reconstruction and Development / The World Bank; 2011.
- 252.
Johnson WD, Hedges LV, Diaz RM. Interventions to modify sexual risk behaviours for preventing HIV infection in men who have sex with men.
Cochrane Database Systematic Reviews. 2003;(1):CD001230. [
PubMed: 12535405]
- 253.
- 254.
- 255.
Pedrana AE, et al. High rates of undiagnosed HIV infections in a community sample of gay men in Melbourne, Australia.
Journal of Acquired Immune Deficiency Syndromes. 2012;59(1):94–98. [
PubMed: 21992925]
- 256.
- 257.
- 258.
Benjamin RJ, et al. International Forum. Deferral of males who had sex with other males.
Vox Sanguinis. 2011;101(4):339–367. [
PubMed: 21992684]
- 259.
Vamvakas EC. Scientific background on the risk engendered by reducing the lifetime blood donation deferral period for men who have sex with men.
Transfusion Medicine Reviews. 2009;23(2):85–102. [
PubMed: 19304111]
- 260.
Vamvakas EC. Why are all men who have had sex with men even once since 1977 indefinitely deferred from donating blood? Editorial.
Transfusion. 2009;49:1037–1042. [
PubMed: 19638153]
- 261.
Galarneau C. Blood donation, deferral and discrimination: FDA donor deferral policy for men who have sex with men.
The American Journal of Bioethics. 2010;10(2):29–39. [
PubMed: 20131170]
- 262.
Seed CR, et al. No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men.
Transfusion. 2010;50:2722–2730. [
PubMed: 20663106]
- 263.
Soldan K, Sinka K. Evaluation of the de-selection of men who have had sex with men from blood donation in England.
Vox Sanguinis. 2003;84:265–273. [
PubMed: 12757500]
- 264.
Germain M, Remis RS, Delage G. The risks and benefits of accepting men who have had sex with men as blood donors.
Transfusion. 2003;43:25–33. [
PubMed: 12519427]
- 265.
Anderson SA, et al. Quantitative estimate of the risks and benefits of possible alternative donor deferral strategies for men who have had sex with men.
Transfusion. 2009;49:1103–1114. [
PubMed: 19320868]
- 266.
Leiss W, Tyshenko M, Krewski D. Men having sex with men donor deferral risk assessment: an analysis using risk management principles.
Transfusion Medicine Reviews. 2008;22(1):35–57. [
PubMed: 18063191]
- 267.
Nash K, Bentley I, Hirschfield G. Managing hepatitis C infection.
British Medical Journal. 2009;338:b2366. [
PubMed: 19561051]
- 268.
Baldo V, et al. Epidemiology of HCV infection.
Current Pharmaceutical Design. 2008;14(17):1646–1654. [
PubMed: 18673187]
- 269.
Dolan K, et al. Reference Group on HIV/AIDS prevention and care among injecting drug users in developing and transitional countries.
The Lancet Infectious Diseases. 2007;7(1):32–41. [
PubMed: 17182342]
- 270.
Leung NW. Management of viral hepatitis C.
Journal of Gastroenterology and Hepatology. 2002;17(Suppl. S1):S146–S154. [
PubMed: 12000600]
- 271.
Pérez CM, Suárez E, Torres EA. Epidemiology of hepatitis C Infection and its public health implications in Puerto Rico.
Puerto Rico Health Sciences Journal. 2004;23(Suppl. 2):11–28. [
PubMed: 16929583]
- 272.
Crampin AC, et al. The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales.
Epidemiology and Infection. 1998;121(2):381–386. [
PMC free article: PMC2809535] [
PubMed: 9825789]
- 273.
Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia.
Drug and Alcohol Dependence. 2002;65(3):303–308. [
PubMed: 11841901]
- 274.
Salmon AM, et al. High HIV testing and low HIV prevalence among injecting drug users attending the Sydney Medically Supervised Injecting Centre.
Australian and New Zealand Journal of Public Health. 2009;33(3):280–283. [
PubMed: 19630850]
- 275.
Macías J, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack.
Liver International. 2008;28(6):781–786. [
PubMed: 18312289]
- 276.
Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response.
American Journal of Public Health. 2006;96(6):974–978. [
PMC free article: PMC1470637] [
PubMed: 16449578]
- 277.
Vescio MF, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis.
Journal of Epidemiology and Community Health. 2008;62(4):305–313. [
PubMed: 18339822]
- 278.
Chandra M, et al. Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India.
Tropical Gastroenterology. 2003;24(4):193–195. [
PubMed: 15164530]
- 279.
Hayes MO, Harkness GA. Body piercing as a risk factor for viral hepatitis: an integrative research review.
American Journal of Infection Control. 2001;29(4):271–274. [
PubMed: 11486271]
- 280.
Hwang Ly, et al. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population.
Hepatology. 2006;44(2):341–351. [
PubMed: 16871571]
- 281.
Oberdorfer A, et al. Infection control practices among tattooists and body piercers in Sydney, Australia.
American Journal of Infection Control. 2003;31(8):447–456. [
PubMed: 14647105]
- 282.
Nishioka Sde A, Gyorkos TW. Tattoos as risk factors for transfusion-transmitted iseases.
International Journal of Infectious Diseases. 2001;5(1):27–34. [
PubMed: 11285156]
- 283.
- 284.
- 285.
Gear S. Rules of engagement: structuring sex and damage in men's prisons and beyond.
Culture, Health & Sexuality. 2005;7:195–208. [
PubMed: 16864198]
